CapsoVision, Inc. stock analysis
Want to see CV full AI Analyst Report?
CapsoVision, Inc. (CV) Stock Price & Analysis
CV Stock Chart & Stats
- Day’s Range
- $6.28 - $6.83
- 52-Week Range
- $4.50 - $15.37
- Previous Close
- $6.82
- Volume
- N/A
- Average Volume (3M)
- 129.52K
- Market Cap
- $365.62M
- Enterprise Value
- $305.69M
- Total Cash (Recent Filing)
- $21.76M
- Total Debt (Recent Filing)
- $780.00K
- Price to Earnings (P/E)
- ―
- Beta
- -1.15
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Differentiated AI Imaging Platform
The combination of panoramic small-bowel imaging and FDA-cleared AI review differentiates CapsoVision’s product from competing capsules. This integrated capability may improve physician efficiency, support clinical adoption, and strengthen the company’s competitive position across hospitals and GI practices.
Regulatory And Product Expansion
FDA clearance and the U.S. launch expand the commercial utility of CapsoCam Plus and validate the company’s development platform. Embedding AI into CapsoView and CapsoCloud can deepen the existing workflow proposition while creating a foundation for broader product adoption.
Revenue Growth With Solid Gross Margins
Sustained trailing revenue growth alongside solid gross margins indicates that the core product has meaningful commercial demand and reasonable underlying economics. If maintained, this combination can support reinvestment in regulatory programs, sales expansion, and future operating leverage.
Bears Say
Significant And Worsening Cash Burn
Persistent negative operating and free cash flow means the business is not yet funding operations internally. The worsening burn increases dependence on financing resources, limits flexibility to invest through a downturn, and raises the importance of achieving meaningful revenue scale and expense discipline.
Very Large Operating And Net Losses
Losses that substantially exceed revenue show that the current cost base is far ahead of the company’s commercial scale. This weak operating leverage can delay profitability, consume available capital, and make future earnings highly dependent on rapid adoption and sustained expense reductions.
Pricing And Margin Pressure
Competitive pricing and a lower quarterly gross margin indicate pressure on the economics of the current product portfolio. Unless product differentiation and scale offset this pressure, constrained gross profit could slow progress toward profitability and reduce funds available for clinical and commercial expansion.
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
What is CapsoVision, Inc.’s market cap?
When is CapsoVision, Inc.’s upcoming earnings report date?
How were CapsoVision, Inc.’s earnings last quarter?
Is CapsoVision, Inc. overvalued?
Does CapsoVision, Inc. pay dividends?
What is CapsoVision, Inc.’s EPS estimate?
How many shares outstanding does CapsoVision, Inc. have?
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CapsoVision, Inc.?
What is the TipRanks Smart Score and how is it calculated?
CapsoVision, Inc. Stock Smart Score
Company Description
CapsoVision, Inc.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kang-Huai Wang
- Employees
- 99
- Website
- capsovision.com
- Address
- 18805 Cox Avenue, Saratoga, CA, 95070, US
CapsoVision, Inc. (CV) Earnings & Revenues
CV Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, driven by FDA clearance and the U.S. launch of AI Highlights, completion of the CapsoCam Colon clinical study, new account growth, expanding patient utilization, financing resources and progress in the pancreatic cancer pipeline. The primary negatives were the competitive U.S. pricing environment, only 1% year-over-year revenue growth, lower gross profit and gross margin, and the company's continuing net loss. Overall, the milestones and strategic progress significantly outweighed the financial and commercial challenges.
View all CV earnings summariesCV Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |








